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Introduction 
In addition to opportunistic infections of the central nervous system (CNS), which are due to 
immunosuppression related to HIV, the latter virus, itself, can cause neuropathological abnormalities 
which are located mainly in the basal ganglia and are characterized by microglial giant cells, reactive 
astrocytosis and perivascular monocytes[1]. This HIV encephalopathy is characterized, clinically, by 
psycho-motor slowing, memory loss, difficulties in complex tasks requiring executive functions, as 
well as motor disorders [2]. These cognitive deficits are grouped under the acronym of HIV-associated 
neurocognitive disorders (HAND) [3].   
 
In fact, HANDs are subdivided in three groups in accordance with the severity of the cognitive 
impairment: Asymptomatic Neurocognitive Impairment (ANI), Mild/moderate Neurocognitive 
Disorders (MND) and HIV Associated Dementia (HAD). 
ANI may be considered as a presymptomatic form of HAND [4]. ANI is defined by a cognitive deficit 
in at least 2 cognitive areas (or domains), with at least one standard deviation below the values of age-
matched healthy subjects. Typically, the deficits consist in impaired attention-concentration, mental 
slowing, decline of the memory, but, in ANI, there is no interference in everyday activities [2]. 
MND is described as cognitive impairment fulfilling the same criteria as ANI, but, in addition, there 
must be interference due to cognitive deficits in the daily activities.  
HAD has the worse impact on the quality of life and survival [4]. It is characterized by at least two 
cognitive domains with values situated two standard deviations below age-matched healthy subjects 
and a severe functional impairment in daily activities. This dementia occurs usually, but not always, 
when the level of CD4+ T lymphocytes is under 200/ul [5]. The incidence of HAD has decreased 
significantly since the introduction of highly active anti-retroviral therapy (HAART) in 1996-1997.  
However, the prevalence of mild cognitive complaints (MND) in HIV+ patients has paradoxically 
increased in the HAART era. There are many potential reasons to explain this state of facts.  
 
First, since its introduction in 1996–1997, HAART has allowed many HIV+ patients to live longer [6]. 
Indeed the number of HIV+ patients older than 50 year-old is dramatically increasing [7]. However, 
this longer duration of HIV disease, together with the increasing age of HIV-infected persons may 
have a detrimental effect on cognitive function, possibly in relation with the development of several 
neurodegenerative diseases [7].  
Another reason is the HAART penetration-effectiveness in the CNS. In fact, there could be limiting 
access of HAART within the brain through anatomical barriers such as the blood-brain barrier. 
Knowing that HIV has a strong neurotropism, its presence in the CNS may trigger and maintain a 
 4 
 
moderately intense inflammatory response, which could be deleterious at term. Letendre et al. 
proposed a pharmacodynamic model to quantify the CNS penetration-effectiveness score (CPE) of 
different antiretroviral drugs [8]. Some validation of this CPE score has been obtained since the lower 
the CPE score, the higher the HIV viral load in the CSF [2]. However, the correlation between the 
CPE score and cognitive functions is missing [9] Therefore, prospective studies are needed to validate 
the CPE score as a clinical tool.  
 
A third possibility is the putative neurotoxicity of HAART in the brain. Until now, there is no solid 
evidence supporting this hypothesis. However, Robertson and al. prospectively performed repeated 
neuro-psychological tests in a cohort of HIV + patients who had elected to discontinue antiretroviral 
therapy. Against all expectations, this study provided Class III evidence that discontinuing ART is 
associated with an improvement in 2 neuropsychological tests (Trail-Making Test A & B and the 
Wechsler Adult Intelligence Scale-Revised Digit Symbol subtest) for up to 96 weeks. However, 
Resuming ART was not associated with a decline in these scores for up to 45 weeks [10]. 
Nevertheless, there were several limitations to this study, one of them being the learning effect. 
Indeed, repeated neuropsychological assessment can result in practice or learning effects and falsely 
improvement in the neuropsychological tests [10]. 
 
Some new studies prove that there are similarities between HAND's and Alzheimer's disease (AD) 
[11].  
Alzheimer’s disease (AD) is an age-related neurodegenerative disease characterized clinically by 
dementia and pathologically by the accumulation of amyloid plaques of neurofibrillary tangles. The 
toxic form of amyloid-β 1-42 is typically decreased in the CSF of HIV-negative patients with 
Alzheimer disease [12].  
Interestingly, Clifford et al. (2009) found low concentration of amyloid-β 1-42 in the CSF of HIV 
patients with HAND, such as it is the case in AD patients. One of the reasons to explain this decrease 
of amyloid-beta in the CSF may be the protein Tat. Tat, a HIV-1 transactivator regulatory protein, is an 
endonuclease which inhibits neprilysin, this enzyme being responsible for amyloid-β breakdown [13]. 
Thus, through this mechanism, HIV infection may block the degradation of amyloid-β 1-42, which 
will lead to an accumulation of this compound in the brain and a decrease of its clearance in the CSF.  
 
In addition to low concentrations of amyloid-β 1-42, the CSF of AD patients is also characterized by 
elevated levels of total Tau (t-Tau) as well as phosphorylated Tau (p-Tau)
 
[7]. Tau is another protein 
involved in AD. The studies looking at the level of total Tau and p-Tau in the CSF of patients with 
HAND are contradictory. Some studies have shown that Tau is elevated in the CSF of HIV+ patients, 
such as it is found in AD [7]
 
and others have described normal levels of Tau [14]. Recently, Gisslen et 
al. did a comprehensive study of several biomarkers and found that the combination in the CSF of a 
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low level of soluble amyloid precursor proteins (sAPP) alpha and beta and a normal level of 
phosphorylated Tau allowed to discriminate patients with HAD from AD patients, but not from those 
HIV+ patients with opportunistic infections. These authors concluded that parallel reductions of CSF 
sAPP in HAD and CNS opportunistic infections suggest an effect of CNS immune activation or 
inflammation on neuronal amyloid synthesis or processing [15]. 
 
However, other markers in the CSF of HIV+ patients may be of interest to try to understand the action 
of HIV in the CNS. One of them is the neopterin who is a product of guanosine triphosphate pathway 
[16]. Neopterin is produced by monocytes/macrophages activated mainly with IFN- . This marker 
seems to provide a stable indicator of the aggregate macrophage activation in the CNS compartment. 
One study
 
[17] showed that high concentrations of neopterin are found in the CSF of patients with 
HAD. Actually, the more elevated is neopterin in the CSF, the more increased the risk of HAD [16]. 
 
S100-β is another potentially interesting biomarker. It is an acidic calcium-binding protein that is 
found in astrocytes. High concentration in CSF may be associated with neuronal apoptosis [16]. 
Elevated CSF concentration increases the risk of HAD.  It has recently been shown that extensive 
astrocyte infection was prominent in patients with HIV-associated dementia, suggesting that astrocytes 
play a prominent role in HIV neuropathogenesis [18]. In another recent study, Eugenin and al. showed 
that, in cell culture, infection with HIV of only 5% of astrocytes was sufficient to cause a disruption of 
the blood-brain barrier. This disruption could increase the permeability to molecules that are normally 
absent in brain parenchyma, including large proteins, which would lead to apoptosis of endothelial 
cells [19]. 
 
An important question is to understand how soon the brain may be affected by HIV. Indeed, the fact 
that well-treated HIV+ patients with undetectable HIV viremia still develop HAND suggests that, in 
these patients, there is a low-grade dysfunction in the CNS that antedates the start of HAART.  Since 
performing a biopsy in these patients is not an issue, the study of the CSF represents the best available 
way to look at putative biomarkers of inflammation/neurodegeneration in the CNS. Such as described 
above, such studies have been performed earlier. However, most of these studies compared HIV+ 
patients without HAND with HAND patients. Here, we decided to look very early, even before the 
onset of HAND, whether there would be early biomarkers indicating a sub-optimal control of HIV in 
the CNS.  
 
To examine how sensitive are the CSF biomarkers to indicate CNS insults caused by HIV, we 
proposed to take advantage of the MOST (Monotherapy Switzerland/Thailand study) study, recently 
published in AIDS [20], and collaborated with Prof. Pietro Vernazza in St-Gall. Prof Vernazza was 
indeed the leading author of this trial, which was supported by the Swiss HIV Cohort Study.    
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In MOST study, monotherapy (MT) consisting in ritonavir-boosted lopinavir (LPV/r) was compared 
to continuous conventional antiretroviral therapy including several molecules, hereafter referred as 
CT.  The rationale for testing a monotherapy was that it may be a potential method to reduce toxicity 
and costs while maintaining full viral suppression [20].  
To be enrolled in MOST, patients needed to be on ART for at least 6 months with suppressed HIV 
RNA in the blood (< 50 copies/ml).  At study termination, 60 patients had been enrolled, including 31 
on CT and 29 on MT for 96 weeks, with an optional switch to monotherapy offered to all patients on 
continued treatment at week 48 [20]. At baseline (CSF#1), week 48 (CSF#2) and study termination 
(CSF#3), patients were supposed to have a lumbar puncture for quantitative HIV- RNA analysis. Since 
the study had to be stopped prematurely, some patients had only two LP’s: CSF#1, corresponding to 
study entrance, and CSF#3, corresponding to study termination whereas the latter could occur before 
week 48.  
The study had to be prematurely stopped because six patients under MT presented HIV-RNA failure in 
blood after around 12 weeks. All 60 patients had a lumbar puncture at baseline and 45 of them at 
study termination (25 MT with blood viral load < 400, 5 failing MT, 15 under CT with blood viral 
load < 50).  
At study termination, the fraction of patients with detectable HIV-RNA in the CSF was significantly 
higher in patients on MT than on CT [20]. 
Whereas no study patient exhibited obvious neuropsychological impairment, the HIV viral load in the 
CSF was detectable in 15 patients. HIV VL was detectable in the CSF of only three patients at study 
entrance (BL), all the others CSF samples came from patients on MT. (see Table 1) 
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Table 1.  Summary of all patients with treatment failure in blood or detection of elevated HIV-RNA in CSF at 
any time during the study (From Gutman C and al., AIDS 2010, 24:2347-2354). 
 
Therefore, this study represents a unique opportunity to examine the CSF of patients whose HIV is 
just beginning to escape therapy. The main goal of our study was thus to determine whether the CSF 
of patients on MT exhibit a different pattern of the one of patients on CT. In particular, we considered 
that it would be particularly interesting to see if any of our biomarkers could be an earlier indicator of 
treatment escape than detectable HIV VL in the CSF [20]. 
 
As discussed above, amyloid-β 1-42, Tau total (tTau), phosphorylated Tau (pTau), Neopterin and 
S100-β are interesting to study as they are representative biomarkers of the major cells of the CNS: 
neurons, macrophages/microglia and astrocytes. Thus, we decided to determine the levels of these five 
biomarkers in the CSF of MOST patients.  
Material and Methods 
Subjects 
Gutmann et al. (2010) enrolled 60 patients in the MOST study. All patients were under 
continued anti-retroviral therapy (cART) for at least 6 month with suppressed HIV-RNA (<50 
copies/ml) for at least 3 months. All patients had a lumbar puncture at baseline and 45 of them at 
study termination (25 MT with blood viral load < 400, 5 failing MT, 15 under CT with blood 
viral load < 50). Cerebrospinal fluid was collected and processed in polypropylenes tubes and 
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stored at -80°C until the time of the assay [20]. Not all CSF samples were available for our 
study, indeed, we obtained a total of 85 samples of CSF corresponding to 49 patients. All these 
85 CSF samples were tested in our lab. Nevertheless, we ended up analyzing 65 CSF samples 
from these 49 patients (see explanations in the statistical analysis).  
In 13 of the tested samples, HIV-RNA in the CSF was elevated at some point during the study. 
Two patients had elevated HIV-RNA in CSF at baseline and eleven later in the course of the 
study, all were on MT (see table 2). 
 
Table 2. Summary of all patients with detection of elevated HIV-RNA in CSF at any time 
during the study 
      Patient ID CSF# Week on study/MT Treatment RNA CSF CD4 nadir (/μl) 
101,mo 3 12 MT 120'000 57 
108,AG 3 60/12 DS 1250 5 
124,VM  3 44 MT 84 17 
126,JB 3 12 MT 96200 149 
302 3 24 MT 14000 7 
 702,BB  3 72/24 DS 130 120 
 703,EC  3 66/18 DS 2330 370 
 704,KS  3 63 MT 20000 100 
 707,SP 3 68/20 DS 2500 130 
 709,dj/BL 1 0 CT 43 20 
709,JD  2 37 MT 250 20 
713 rb/BL 1 0 CT 4800 160 
 714,BN  2 48 MT 320 220 
      Table 2: CSF#1 : Lumbar puncture at baseline, CSF#2:  lumbar puncture at 48 weeks, CSF#3 : 
lumbar puncture at study termination, MT : monotherapy, CT: conventional therapy, DS: 
Delayed switch (passage from CT to MT )  
 
As controls, we used the CSF of 37 HIV-negative patients suffering from dementia (AD patients) that 
had been collected between 1999 and 2008 in the CSF/serum bank of the Division of Neurology of the 
CHUV. Thirty patients were diagnosed with Alzheimer’s disease and 7 patients with frontotemporal 
dementia.CSF was collected and processed in polypropylenes tubes and stored at -80°C until the time 
of the assay.  
Enzyme- Linked Immunosorbent Assay (ELISA)  
To determine the presence of the five different biomarkers, we performed Enzyme- Linked 
Immunosorbent Assay (ELISA) according to manufacturer instructions. Principle of a solid 
phase sandwich is described in the figure.1. 
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Figure 1 (1) Plate is coated with a capture antibody ; (2) sample is added, and if the studied antigen is present, it 
will  bind to capture antibody ; (3) After washing, a rabbit polyclonal antibody specific for the given antigen is 
added and binds to it; (4) antibody against the detection antibody, such as an anti-rabbit, and coupled to HRP is 
added, and binds to detecting antibody ; (5) After a third incubation and washing to remove all the excess anti-
rabbit HRP, a substrate solution is added, which will bind to the enzyme to produce color. The intensity of the 
color is proportional to the concentration of biomarkers. I thank Joana Le Boudec for this figure.  
 
Amyloid-  1-42 (Aβ42) 
CSF concentrations of Amyloid-  1-42 were determined with the Invitrogen Human Aβ42 US kit 
(Invitrogen, Camarillo, CA). This assay is specific for the COOH-terminus of the 1-42 Aβ sequence. 
This COOH-terminal sequence is created upon cleavage of the analyzed precursor. Absorbance was 
read with a spectrophotometer at 450 nm. The minimum detectable dose of Hu Aβ42 is 1.0 pg/mL. 
Samples were diluted for the assay and measured values were multiplied by the appropriate factor for 
the sample dilution. We analysed 85 samples of MOST study patients and 36 samples from AD 
patients. 
 
Phosphorylated Tau (pTau) 
CSF concentrations of phosphorylated tau (pTau) were determinded by an ELISA kit from Invitrogen 
(Camarillo, CA) and the Innotest Phospho-Tau (181p) ELISA from Innogenetics (Gent, Belgium). The 
minimum detectable dose of Hu Tau [pT181] is 10 pg/mL for Invitrogen ELISA kit and 15.6 pg/ml 
for Innotest Phospho-Tau ELISA. Samples were diluted for the assay and measured values were 
multiplied by the appropriate factor for the sample dilution. Forty-one samples from patients included 
in the MOST study were tested with the Invitrogen ELISA kit. Subsequently, Innotest Phospho-Tau 
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(181p) from Innogenetics was used for the remaining 44 MOST study patients and for 36 sample from 
AD patients  
 
Total Tau (tTau) 
CSF concentrations of tTau were determined by ELISA Invitrogen (Camarillo, CA, 2010). The 
minimum detectable dose of Hu Tau is 12 pg/mL. Samples were diluted for the assay and measured 
values were multiplied by the appropriate factor for the sample dilution. 
 
S100-  
CSF concentrations of S 100-  were determined by Human S100B ELISA Kit (Abnova, Ville, Pays). 
Samples were diluted for the assay and measured values were multiplied by the appropriate factor for 
the sample dilution. This kit has a limit of detection of 15 pg/ml.  
 
Neopterin 
CSF concentrations of neopterin were determined by the ELISA kit ( RE59321) of  IBL (Hamburg, 
Germany,2008). For this ELISA, the intensity of the color developed after the substrate incubation is 
inversely proportional to the amount of antigen. Sample limit detection was 0.7 nmol/l .  
Statistical analysis  
In MOST study, each patient was supposed to undergo three LP’s. One at study entrance 
(CSF#1), one at 48 weeks (CSF#2) and one at study termination (CSF#3), which was initially 
supposed to take place at week 96. However, this study was prematurely halted due to HIV VL 
failure in six patients. Therefore, only a minority of patients had all three CSF samples. 
Furthermore, we were not able to obtain all the CSF samples that had effectively been collected 
(loss of samples, insufficient CSF remaining, etc.). Thus, as we were interested in the effect of 
MT versus CT on CSF biomarkers, we decided to analyze the CSF corresponding to the longest 
time spent on CT, respectively on MT. This way of analysis allowed us to optimize the amount 
of samples at our disposal. For instance, if a patient was all along the study on CT, we analyzed 
only the last available CSF sample. However, if a patient was switched at week 48 from CT to 
MT, we analyzed the CSF at 48 week in the CT group, since it corresponded to the longest 
possible time spent on CT, and we analyzed the values of the CSF#3 (corresponding to study 
termination) in the MT group (whenever this third LP was performed between 48 weeks and 96 
weeks).  Finally, for patients who were put right away on MT, we used the entrance study CSF 
for CT (since it was an enrollment condition that all patients were on CT at study entrance) and, 
for MT, the CSF sample corresponding to the timepoint the patient had spent the longest time on 
MT.  
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Such as mentioned above, we enrolled patients with dementia (mostly AD) since several authors 
have drawn parallels between neurodegenerative diseases and CNS repercussion of HIV 
infection. Thus, we compared the CSF corresponding to the lengthiest time spent on CT or MT 
with the CSF of dementia patients. 
Statistical analysis was performed with GraphPad Prism software (GraphPad Software, San Diego, 
CA, USA). The difference between two groups was tested using the non-parametric Mann–Whitney 
ranked test.  
Results 
The results are summarized in Table 3 and Figures 2 to 4.   
 
Table 3 
Median values +/- interquartile CSF concentration  of 
the five biomarkers in all three categories of study 
patients (in pg/ml, median +/- interquartile ranges) 
  
      
  
      
      
 
Aβ42  pTau  tTau  Neopterin S100-β 
MT 391 ± 444 30 ±  36 199 ± 196 2.7 ± 4.6 499 ± 1125 
CT 466 ± 489 35 ± 41 150 ± 153 1.2 ± 2.5 0 ± 532 
AD 234 ± 328 46 ± 98 270 ± 414 1.1 ± 0.9 174 ± 214 
 
Remark: for AD patients, S100-β was measured in the CSF of all 37 AD patients; however, the four 
other biomarkers were measured only in 36 CSF samples of AD patients due to the minimal amount of 
CSF at disposal in AD patient#37.  
 
Group differences in CSF biomarkers   
 
Figures 2, 3, and 4 show comparisons of the CSF levels for the five biomarkers between MT and CT, 
MT and AD, and CT and AD, respectively.  
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Figure 2 Comparison between MT and CT for the five CSF biomarkers. 
S100β (p = 0.0048) and Neopterin (p = 0.0128) were significantly elevated in MT patients as 
compared to CT. We found no significant difference for the three other biomarkers between the two 
categories of study patients. Red points correspond to patients with detectable HIV RNA in the CSF at 
any time point during the study (see table 2) 
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Figure 3 Comparison between MT and AD for the five CSF biomarkers 
S100β (p = 0.0018) and Neopterin (p = 0.0002) were significantly elevated in MT patients as compared to AD. 
Aβ42 (p = 0.0035) was significantly lower in AD patients as compared to MT. We found no significant 
difference for the two other biomarkers between the two categories of study patients.  
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Figure 4 between CT and AD for the five CSF biomarkers 
 tTau ( p = 0.0075) was significantly elevated in AD patients as compared to CT.  Aβ42 (p = 0.0065) was 
significantly lower in AD patients as compared to CT. We found no significant difference for the other 
biomarkers.  
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Second step of analysis: 
In order to determine how sensitive our biomarkers were, we removed from the analysis the 
patients with blood failure who led to study termination, i.e. subjects 101, 108, 126, 302, 303, 
and 713. Indeed, in these patients, the fact that the HIV VL became detectable on MT precluded 
the usefulness of CSF biomarkers. Thus we kept only those who had undetectable HIV VL in 
the blood at study termination . As we had not received CSF#2 or #3 from 303 and never 
received any CSF from 713, we ended up with four CSF samples to remove, corresponding to 
CSF#2 of 101, CSF#3 of 108, CSF#2 of 126, and CSF#2 of 302. However, we kept CSF#1 of 
126 and 302 and CSF#2 of 108 since these CSF were taken while the patients were on CT. The 
results are summarized in figures 5 (MT vs CT) and 6 (MT vs AD). By definition, since the six 
patients with detectable HIV VL in the blood were all in the MT category, there was no change 
in the CT versus AD figure.  
 
 
Figure 5 between MT and CT for the five CSF biomarkers 
S100β (p = 0.0018) was significantly elevated in MT patients as compared to CT. We found no 
significant difference for the four other biomarkers between the two categories of study patients, 
although there was a strong trend for an increased level of neopterin in MT as compared to CT. 
 
 16 
 
 
Figure 6  between MT and AD for the five CSF biomarkers 
S100β (p = 0.0006) and Neopterin (p = 0.0014) were significantly elevated in MT patients as compared to AD.  
Aβ42 (p = 0.0035) was significantly lower in AD patients as compared to MT. We found no significant 
difference for the two other biomarkers between the two categories of study patients 
 
Limitations 
 
Limitation of this study could be the fact that we couldn't make ELISA with the same conditions for 
pTau. Actually, there were an interuption of the stock at the end of the first plate with ELISA kit from 
Invitrogen (Camarillo, CA).  We continue the two last plates with another ELISA kit the Innotest 
Phospho-Tau (181p) ELISA from Innogenetics (Gent, Belgium). Forty-one samples from patients 
included in the MOST study ( 14 CT and 27 MT) were tested with the Invitrogen ELISA kit. 
Subsequently, Innotest Phospho-Tau (181p) from Innogenetics was used for the remaining 44 MOST 
study patients (20 CT and 24 MT) and for 37 AD patients.  
However we found no difference between the method and the results of both ELISA, such as 
displayed in Figure 7.  
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Figure 7 Comparison between two kits of pTau. There are no differences between the groups 
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Discussion 
MT vs CT 
 
First, we found that the CSF of patients on MT contained significantly higher levels of S100β 
than the CSF of CT or AD patients. These finding suggests that the astrocytes were damaged in 
patients on MT. Actually, Euginin and al., found that only few percentage of infected Astrocytes 
could cause a disruption of the blood-brain barrier, leading to an increased influx of cells and 
macro-molecules from the blood into the brain. Such an influx could contribute to the low-grade 
inflammation that is suspected to take place in the brain of patients under sub-optimal 
antiretroviral therapy. The MOST study had to be stopped due to blood HIV VL becoming 
detectable in six patients. When the CSF were analyzed, additional patients were found to have 
detectable HIV VL in the CSF (table 1). Thus, we know from MOST study that MT patients 
were sub-optimally treated, however, many of them had undetectable HIV VL in the blood and 
in the CSF (Figures 2 and 3). Yet, several of these patients were found to have elevated S100 . 
Therefore, we propose that S100  is a very early marker of suboptimal response to antiretroviral 
therapies. The promising value of S100  as a biomarker is further suggested by the fact that the 
difference between MT and CT or AD was maintained even when patients with detectable HIV 
VL in the blood (those who led to study cessation) were removed from the analysis (Figures 5 
and 6). It also may explain why some patients on antiretroviral therapy and undetectable HIV 
VL in the CSF still develop cognitive impairment in long-term. Second, our data suggest that 
astrocytes may be crucial players in the pathogenesis of HIV encephalopathy, and thus possibly 
of HIV-associated neurocognitive disorders. Indeed, S100  at high doses causes neuronal 
apoptosis both via a direct action on neurons and via stimulation of nitric oxide (NO) release by 
astrocytes [21].  
 
We also found that patients on MT had significantly higher CSF neopterin than CT or AD. Such 
as stated in the Introduction, neopterin is a marker of macrophages / microglia and thus suggests 
that inflammation goes on in the CNS of those patients with elevated CSF neopterin. With the 
notable difference, when compared to S100 , that when we removed the patients with 
detectable HIV VL in the blood, the difference between MT and CT disappeared (Figure 5), 
even if a strong trend remained. These data suggest that neopterin may be less sensitive than 
S100  to detect  CNS inflammation in the brain of HIV+ patients. Nevertheless, neopterin has 
been much more studied that S100  as a biomarker of inflammation in the brain of HIV+ 
patients [22,23]. Another difference with S100  is that neopterin correlated better with the 
increased CSF HIV VL in patients. This feature suggests that the inflammation in the brain 
parallels the replication of HIV, which gives weight to neopterin as a good indicator of sub-
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optimal therapy. However, it also means that neopterin is somewhat redundant with HIV VL in 
the CSF to identify patients who fail on anti-retroviral therapy.  
Some study [17] shows that there is a correlation between concentration of neopterin and 
severity of the cognitive disorders. However, we cannot confirm this fact in the current study 
since MOST study patients had not been formally tested by a neuro-psychological battery.  
 
Finally, we found no significant difference in terms of CSF Aβ42, Total tau, and pTau between 
patients on MT and patient on CT. In another study, authors [14, 15] have shown that there were 
difference in terms of CSF Aβ42, pTau and tTau  between HIV+ patients with cognitive 
impairment and controls. However, in the MOST cohort, cognitive functions were not assessed. 
Based on our data, we hypothesize that the very first signs of sub-optimal response to anti-
retroviral therapies are inflammation (neopterin) and astrocytic damage (S100β). Neuronal 
damages, such as reflected by elevated Tau, are a latter process.  
AD vs CT 
First, we found that patient on CT had lower Total Tau CSF than AD patients. Many studies [12] 
demonstrated that high total- and p-tau and low Aβ42 in the CSF are characteristic of AD.  In 
our study, the CSF neuronal markers of patients on CT were at values similar to what is 
described in the literature for healthy subjects [12]. Indeed, CT had lower tTau and higher Aβ42 
as compared to AD patients.  
MT vs AD 
First, we noticed that S100β and neopterin were significantly elevated in the CSF of MT as 
compared to AD patients. Of note, such differences were absent when CT was compared to AD. 
Thus these findings suggest that inflammation and astrocytic damages are restricted to MT 
patients and are not a feature of AD.  
Such as for CT, the Aβ42 in the CSF of MT patients was significantly higher than in AD 
patients, suggesting that there is no dysregulation of the pathway of amyloid, even in sub-
optimally treated HIV+ patients. However, contrasting with CT, there was no longer differences 
in terms of tTau between MT and AD patients. These data point to early development of 
neuronal damages in the brain of patients on MT, thus suggesting that the microglial and 
astrocytic damages are rapidly impacting on neurons. Nevertheless, the fact that tTau was not 
significantly higher in the CSF of MT as compared to CT ponders this observation. Thus, we 
cannot rule out that the observed difference between MT and AD  may just be due to chance.  
In conclusion, we consider that Neopterin and especially, S100β, are promising early biomarkers of 
sub-optimal response to antiretroviral therapy in the CNS of HIV+ patients.   
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In conclusion, we foreground two early biomarkers of HIV neurodegenerative process, S100β and 
neopterin. It will be very interesting to care of the evolution of these markers according to severity and 
differents stages of HIV-associated neurocognitive disorders (HAND). Better understand this 
neurodegenerative process is an important stake for the new search about HIV patients.  Actually, 
results of those new studies could develop more effective therapy.  
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